Clinical trial news

AnnePariser, RaDaR

RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site was developed by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of…

big sister

Zolgensma (onasemnogene abeparvovec-xioi), the newly approved gene therapy to treat SMA in infants and children under 2 years old, works by delivering directly to motor neurons a healthy copy of the SMN1 gene that is damaged by mutations in these patients and unable to make an essential protein. Carried…

reldesemtiv

The U.S. Food and Drug Administration approved the six-minute walk test (6MWT) as an acceptable primary endpoint, or goal, for a potential registration program of the investigational treatment reldesemtiv for spinal muscular atrophy (SMA) patients who are able to walk. In the feedback provided to therapy developer Cytokinetics, the agency…